


New approach to robustly producing functional human pancreatic β cells for curing diabetes

March 7 2022



Credit: Zhejiang University

Diabetes, a global chronic disease, affects millions of people worldwide. Islet transplantation holds immense promise as a cure for diabetes, but it is circumscribed by shortage of organ donors and immunosuppression issues. Differentiation of Human pluripotent stem cells (hPSCs) is regarded as an effective solution to cell-based therapy.

On February 23, Prof. Zhu Saiyong's lab at the Zhejiang University Life Sciences Institute published an article entitled "Human expandable

pancreatic progenitor-derived β cells ameliorate diabetes" in the journal *Science Advances*. In this study, Zhu Saiyong et al., for the first time, achieved the long-term goal of robust expansion of pancreatic progenitors (PPs).

In this study, the researchers differentiated hPSCs into PPs. Through [chemical screening](#), the team discovered that I-BET151 could significantly boost the expansion of PDX1+NKX6.1+ PPs. They established an effective approach to producing expendable PPs (ePPs). In this way, ePPs could be stably frozen and recovered, thereby achieving their long-term and stable robust expansion. During the culturing process, these ePPs maintained the characteristics of progenitors, stable karyotypes and self-renewal abilities. Notably, these PPs could be efficiently differentiated into functional ePP- β cells and islet-like organoids. Transplantation of ePP- β cells rapidly ameliorated diabetes in mice, suggesting enormous potential for cell replacement therapy. Mechanistically, I-BET151 could activate Notch signaling and promote the expression of key PP-associated genes, underscoring the importance of epigenetic and transcriptional modulations for lineage-specific progenitor self-renewal.

"This study represents a notable step toward providing unlimited functional human pancreatic β cells and islets that are of considerable interest for [biomedical research](#) and [regenerative medicine](#)," said Prof. Zhu.

More information: Xiaojie Ma et al, Human expandable pancreatic progenitor-derived β cells ameliorate diabetes, *Science Advances* (2022). [DOI: 10.1126/sciadv.abk1826](https://doi.org/10.1126/sciadv.abk1826)

Provided by Zhejiang University

Citation: New approach to robustly producing functional human pancreatic β cells for curing diabetes (2022, March 7) retrieved 25 April 2024 from

<https://medicalxpress.com/news/2022-03-approach-robustly-functional-human-pancreatic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.